๐๐ฅ๐๐ฏ๐๐ญ๐ ๐๐จ๐ฎ๐ซ ๐๐จ๐ฅ๐ ๐๐๐ฆ๐ ๐ฐ๐ข๐ญ๐ก ๐๐๐๐ ๐๐ข๐ฅ๐๐ง๐จ ๐๐ง๐ ๐๐๐ข๐ฌ๐ฌ ๐๐จ๐ฅ๐...
Breaking News Update: AEYE Healthโs #AI for Diabetic Retinopathy and Alconโs Acquisition of BELKIN Vision.
In the latest news from the eye care industry, two mayor developments are set to make waves. The #FDA has approved AEYE Healthโs fully autonomous AI system for diagnosing diabetic retinopathy (DR), a groundbreaking advancement that could significantly improve early detection and patient outcomes. Additionally, Alcon is acquiring Belkin Vision in a deal worth up to $335 million, reinforcing its position in glaucoma surgery.
๐ AEYE Healthโs newly approved Diagnostic Screening system (AEYE-DS) represents a milestone in AI-driven healthcare. Designed for diabetic patients aged 22 and older with no prior DR diagnosis, the system uses a desktop camera to analyse retinal images and deliver results in just one minute. This is a drastic reduction in time compared to traditional screenings, which typically take 15 to 20 minutes. Furthermore, FDA clearance allows AEYE-DS to use a portable handheld device, making the technology more accessible and easier to use in various settings.
๐ Alconโs Acquisition of Belkin Vision for Glaucoma Surgery
Meanwhile, Alcon's acquisition of Belkin Vision strengthens its position in glaucoma surgery. Belkin Vision's Eagle device is an innovative laser system that offers a non-invasive solution for Selective Laser Trabeculoplasty (SLT), delivering laser energy through a non-contact approach via the cornea. This simplifies glaucoma surgery and adds to Alcon's robust portfolio of minimally invasive glaucoma surgery (MIGS) devices, especially following its 2022 acquisition of Ivantis, known for the Hydrus Microstent.
With FDA clearance already in place, Alcon's acquisition is expected to expedite the commercial availability of the Eagle SLT device in the US market.
